微RNA-mRNA网络与炎症和免疫系统调节有关的炎症性肠病
Carina de F de Síbia1, Ana E V Quaglio2, Ellen C S de Oliveira3
1Department of Surgery and Orthopedics, Botucatu Medical School, São Paulo State University (UNESP), Botucatu 18618-687, SP, Brazil.
Biomedicines
|February 24, 2024
概括
微RNAs (miRNAs) 在克罗恩病 (CD) 和性结肠炎 (UC) 中受到放松,影响免疫调节. 已识别的miRNA及其标显示出作为诊断和治疗炎症性肠病 (IBD) 的生物标志物的潜力.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 克罗恩病 (CD) 和性结肠炎 (UC),炎症性肠病 (IBD) 的形式的分子基础,仍然不完全理解.
- 微RNAs (miRNAs) 是基因表达的关键调节者和慢性疾病的新兴生物标志物.
研究的目的:
- 在CD和UC中识别全球miRNA表达模式.
- 在IBD中识别miRNA点基因及其相关的生物功能.
- 构建与IBD病变发生相关的miRNA-mRNA相互作用网络.
主要方法:
- 一项元分析整合了来自九项IBD研究的miRNA表达数据.
- 生物信息工具 (microRNA数据集成门户,ToppGene套件) 用于识别miRNA目标和丰富的途径.
- 分析包括使用欧洲生物信息研究所 (EBI) 数据库对肠组织表达的基因进行过.
主要成果:
- 在CD中15个miRNAs的上调和6个miRNAs的下调;在UC中33个miRNAs的上调和7个miRNAs的下调.
- 与CD相比,UC表现出更大的miRNA放松调节.
- 在免疫系统调节途径中,miRNA标被丰富,特定的miRNA (例如,CD中的miR-199a-5p,CD中的miR-362-3p;UC中的miR-155-5p) 显示出显著的变化.
结论:
- 已识别的miRNAs调节了参与IBD免疫反应和炎症的基因.
- 这些miRNA及其标代表IBD的潜在临床相关生物标志物.
- 这些发现可能会提高诊断准确度,并为IBD患者指导个性化治疗策略.
相关概念视频
MicroRNAs
21.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.3K
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163


